Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.05
SRNE's Cash-to-Debt is ranked lower than
77% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. SRNE: 2.05 )
Ranked among companies with meaningful Cash-to-Debt only.
SRNE' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.34  Med: No Debt Max: No Debt
Current: 2.05
Equity-to-Asset 0.24
SRNE's Equity-to-Asset is ranked lower than
90% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SRNE: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
SRNE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17  Med: 0.76 Max: 0.95
Current: 0.24
0.17
0.95
Debt-to-Equity 0.29
SRNE's Debt-to-Equity is ranked lower than
65% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. SRNE: 0.29 )
Ranked among companies with meaningful Debt-to-Equity only.
SRNE' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03  Med: 0.09 Max: 0.59
Current: 0.29
-0.03
0.59
Piotroski F-Score: 3
Altman Z-Score: -0.82
Beneish M-Score: -0.81
WACC vs ROIC
13.24%
-155.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -395.24
SRNE's Operating Margin % is ranked lower than
74% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. SRNE: -395.24 )
Ranked among companies with meaningful Operating Margin % only.
SRNE' s Operating Margin % Range Over the Past 10 Years
Min: -4710.43  Med: -908.29 Max: -265.3
Current: -395.24
-4710.43
-265.3
Net Margin % -220.46
SRNE's Net Margin % is ranked lower than
70% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. SRNE: -220.46 )
Ranked among companies with meaningful Net Margin % only.
SRNE' s Net Margin % Range Over the Past 10 Years
Min: -4763.26  Med: -829.62 Max: -220.46
Current: -220.46
-4763.26
-220.46
ROE % -38.52
SRNE's ROE % is ranked lower than
68% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. SRNE: -38.52 )
Ranked among companies with meaningful ROE % only.
SRNE' s ROE % Range Over the Past 10 Years
Min: -93.12  Med: -57.07 Max: -36.09
Current: -38.52
-93.12
-36.09
ROA % -9.88
SRNE's ROA % is ranked higher than
58% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. SRNE: -9.88 )
Ranked among companies with meaningful ROA % only.
SRNE' s ROA % Range Over the Past 10 Years
Min: -2463.64  Med: -48.56 Max: -9.88
Current: -9.88
-2463.64
-9.88
ROC (Joel Greenblatt) % -272.33
SRNE's ROC (Joel Greenblatt) % is ranked lower than
54% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. SRNE: -272.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SRNE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2613.7  Med: -869.22 Max: -254.29
Current: -272.33
-2613.7
-254.29
3-Year Revenue Growth Rate 73.50
SRNE's 3-Year Revenue Growth Rate is ranked higher than
92% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SRNE: 73.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SRNE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 73.5
Current: 73.5
0
73.5
3-Year EBITDA Growth Rate -4.00
SRNE's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SRNE: -4.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SRNE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.9 Max: 272.9
Current: -4
0
272.9
3-Year EPS without NRI Growth Rate -6.10
SRNE's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. SRNE: -6.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SRNE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.9 Max: 238.7
Current: -6.1
0
238.7
» SRNE's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SRNE Guru Trades in Q4 2015

Paul Tudor Jones 44,709 sh (New)
Jim Simons 29,190 sh (New)
» More
Q1 2016

SRNE Guru Trades in Q1 2016

Jim Simons 53,890 sh (+84.62%)
Paul Tudor Jones 35,500 sh (-20.60%)
» More
Q2 2016

SRNE Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q2 2017

SRNE Guru Trades in Q2 2017

Jim Simons 61,763 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SRNE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 8731
Compare:NAS:RGLS, NAS:GTXI, NAS:PPHM, NAS:AXSM, OTCPK:EGRN, NAS:TRVN, NAS:ADVM, NAS:CDTX, NAS:DMTX, NAS:XBIT, NAS:XOMA, AMEX:SYN, NAS:CBMG, NAS:GNCA, OTCPK:ARTH, NAS:ALDX, NAS:LIFE, OTCPK:HPPI, NAS:BDSI, AMEX:MTNB » details
Traded in other countries:8STN.Germany,
Headquarter Location:USA
Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases.

Sorrento Therapeutics is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates.

Ratios

vs
industry
vs
history
PB Ratio 1.45
SRNE's PB Ratio is ranked higher than
79% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. SRNE: 1.45 )
Ranked among companies with meaningful PB Ratio only.
SRNE' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 5.06 Max: 225.52
Current: 1.45
1.28
225.52
PS Ratio 6.63
SRNE's PS Ratio is ranked higher than
56% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. SRNE: 6.63 )
Ranked among companies with meaningful PS Ratio only.
SRNE' s PS Ratio Range Over the Past 10 Years
Min: 5.87  Med: 85.03 Max: 7291.67
Current: 6.63
5.87
7291.67
EV-to-EBIT -3.01
SRNE's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. SRNE: -3.01 )
Ranked among companies with meaningful EV-to-EBIT only.
SRNE' s EV-to-EBIT Range Over the Past 10 Years
Min: -181.6  Med: -9.7 Max: 123.3
Current: -3.01
-181.6
123.3
EV-to-EBITDA -3.49
SRNE's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. SRNE: -3.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRNE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -182.8  Med: -10.45 Max: 67.3
Current: -3.49
-182.8
67.3
EV-to-Revenue 6.95
SRNE's EV-to-Revenue is ranked higher than
52% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. SRNE: 6.95 )
Ranked among companies with meaningful EV-to-Revenue only.
SRNE' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.4  Med: 81.8 Max: 6830.6
Current: 6.95
5.4
6830.6
Current Ratio 0.76
SRNE's Current Ratio is ranked lower than
93% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. SRNE: 0.76 )
Ranked among companies with meaningful Current Ratio only.
SRNE' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.95 Max: 18.58
Current: 0.76
0.59
18.58
Quick Ratio 0.76
SRNE's Quick Ratio is ranked lower than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. SRNE: 0.76 )
Ranked among companies with meaningful Quick Ratio only.
SRNE' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 5.95 Max: 18.58
Current: 0.76
0.59
18.58
Days Sales Outstanding 88.80
SRNE's Days Sales Outstanding is ranked lower than
74% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. SRNE: 88.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRNE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.09  Med: 131.46 Max: 312.63
Current: 88.8
42.09
312.63
Days Payable 1.00
SRNE's Days Payable is ranked lower than
92% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. SRNE: 1.00 )
Ranked among companies with meaningful Days Payable only.
SRNE' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 2011.64 Max: 196461.25
Current: 1
1
196461.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -30.20
SRNE's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. SRNE: -30.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRNE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -569.4  Med: -51.1 Max: 0
Current: -30.2
-569.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.08
SRNE's Price-to-Median-PS-Value is ranked higher than
97% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SRNE: 0.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRNE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.94 Max: 85.78
Current: 0.08
0.08
85.78
Earnings Yield (Greenblatt) % -33.17
SRNE's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. SRNE: -33.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRNE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -86.9  Med: -9.65 Max: 1.8
Current: -33.17
-86.9
1.8

More Statistics

Revenue (TTM) (Mil) $15.80
EPS (TTM) $ -0.61
Beta1.83
Short Percentage of Float5.49%
52-Week Range $1.50 - 8.35
Shares Outstanding (Mil)76.54

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 18 35 109 151
EPS ($) -1.05 -0.68 -0.27 -0.06
EPS without NRI ($) -1.05 -0.68 -0.27 -0.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
37.00%
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}